Association between Interleukin-33 Expression and Coronary Heart Disease: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 CHENXiang-jun , CHENMin , ZHANGLei , LINian , LIUFang , HUANGYing-de

Department of Medical Quality Control, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

Keywords：

Interleukin-33; Coronary heart disease; Correlation; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20150088

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the association of interleukin-33 (IL-33) expression and coronary heart disease (CHD). Methods We searched The Cochrane Library, PubMed, EMbase, CBM, VIP, CNKI and WanFang Data up to June 30^th, 2014, to collect case-control studies concerning the association of IL-33 expression with CHD. Two reviewers independently screened literature according the inclusion and exclusion criteria, extracted data and assessed the methodological quality of included studies; and then, meta-analysis was performed using the RevMan 5.2 software. Results Six case-control studies were included. The results of meta-analysis showed that:there were no significant differences in the levels of IL-33 between stable angina pectoris or ST-elevation myocardial infarction patients and healthy population (MD=-25.15, 95%CI -51.08 to 0.77, P=0.06; MD=-28.97, 95%CI -62.89 to 4.95, P=0.09). However, there were significant differences in the levels of IL-33 between unstable angina pectoris or non-ST-elevation myocardial infarction patients and healthy population (MD=-24.79, 95%CI -50.00 to 0.42, P=0.05; MD=-14.60, 95%CI -20.09 to -9.12, P<0.000 01). Conclusion IL-33 expression may be associated with unstable angina pectoris and non-ST-elevation myocardial infarction patients.

Citation： CHENXiang-jun, CHENMin, ZHANGLei, LINian, LIUFang, HUANGYing-de. Association between Interleukin-33 Expression and Coronary Heart Disease: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2015, 15(5): 524-528. doi: 10.7507/1672-2531.20150088 Copy

1.	贾永亮, 张时开, 鲍菲飞, 等. 通心络胶囊与丹参滴丸治疗冠心病心绞痛间接比较的系统评价. 中国循证医学杂志, 2011, 11(8):919-931.
2.	Rifai N, Ridker PM. Inflammatory markers and coronary heart disease. Curr Opin Lipidol, 2002, 13(4):383-389.
3.	Jarvie JL, Whooley MA, Regan MC, et al. Effect of Physical Activity Level on Biomarkers of Inflammation and Insulin Resistance Over 5 Years in Outpatients With Coronary Heart Disease (from the Heart and Soul Study). Am J Cardiol, 2014, 114(8):1192-1197.
4.	Tedgui A, Mallat Z. Cytokines in atherosclerosis:pathogenic and regulatory pathways. Physiol Rev, 2006, 86(2):515-581.
5.	Ammirati E, Moroni F, Magnoni M, et al. The Role of T and B Cells in Human Atherosclerosis and Atherothrombosis. Clin Exp Immunol, 2015, 179(2):173-187.
6.	Willems S, Hoefer I, Pasterkamp G. The role of the Interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment. Minerva Med, 2012, 103(6):513-524.
7.	Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med, 2008, 205(2):339-346.
8.	Liu CL, Shen DL, Zhu K, et al. Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina. Clin Invest Med, 2013, 36(4):E234-241.
9.	Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease:relation to disease activity and adverse outcome. PLoS One, 2014, 9(4):e95055.
10.	Guzel S, Serin O, Guzel EC, et al. Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction. Korean J Intern Med, 2013, 28(2):165-173.
11.	范天全, 于海奕, 郭艳红, 等. 急性冠状动脉综合征患者血浆白细胞介素33 浓度变化及其与预后的关系. 临床荟萃, 2009, 24(11):924-927.
12.	Liu CL, Shen DL, Zhu K, et al. Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease. Coron Artery Dis, 2014, 25(6):498-504.
13.	张祎. 冠心病患者血清IL-33水平的研究. 长沙:中南大学, 2010.
14.	王建华, 肖蕾, 何丽云, 等. 心脑合病危险因素的横断面调查. 中国循证医学杂志, 2014, 14(4):408-413.
15.	Golovkin AS, Ponasenko AV, Khutornaya MV, et al. Association of TLR and TREM-1 gene polymorphisms with risk of coronary artery disease in a Russian population. Gene, 2014, 550(1):101-109.
16.	Franco A, Touma R, Song Y, et al. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity, 2014, 47(2):95-104.
17.	Ismahil MA, Hamid T, Bansal SS, et al. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure:critical importance of the cardiosplenic axis. Circ Res, 2014, 114(2):266-282.
18.	Baekkevold ES, Roussigné M, Yamanaka T, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol, 2003, 163(1):69-79.
19.	Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA, 2008, 105(31):10913-10918.
20.	Brunner SM, Schiechl G, Falk W, et al. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int, 2011, 24(10):1027-1039.
21.	MartinezFO, Sica A, Mantovani A, et al. Macrophage activation andpolarization. Front Biosci, 2008, 13:453-461.
22.	Milovanovic M, Volarevic V, Radosavljevic G, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res, 2012, 52(1-2):89-99.
23.	Zhang K, Zhang XC, Mi YH, et al. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin Med J (Engl), 2013, 126(19):3628-3631.

1. 贾永亮, 张时开, 鲍菲飞, 等. 通心络胶囊与丹参滴丸治疗冠心病心绞痛间接比较的系统评价. 中国循证医学杂志, 2011, 11(8):919-931.
2. Rifai N, Ridker PM. Inflammatory markers and coronary heart disease. Curr Opin Lipidol, 2002, 13(4):383-389.
3. Jarvie JL, Whooley MA, Regan MC, et al. Effect of Physical Activity Level on Biomarkers of Inflammation and Insulin Resistance Over 5 Years in Outpatients With Coronary Heart Disease (from the Heart and Soul Study). Am J Cardiol, 2014, 114(8):1192-1197.
4. Tedgui A, Mallat Z. Cytokines in atherosclerosis:pathogenic and regulatory pathways. Physiol Rev, 2006, 86(2):515-581.
5. Ammirati E, Moroni F, Magnoni M, et al. The Role of T and B Cells in Human Atherosclerosis and Atherothrombosis. Clin Exp Immunol, 2015, 179(2):173-187.
6. Willems S, Hoefer I, Pasterkamp G. The role of the Interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment. Minerva Med, 2012, 103(6):513-524.
7. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med, 2008, 205(2):339-346.
8. Liu CL, Shen DL, Zhu K, et al. Levels of interleukin-33 and interleukin-6 in patients with acute coronary syndrome or stable angina. Clin Invest Med, 2013, 36(4):E234-241.
9. Demyanets S, Speidl WS, Tentzeris I, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease:relation to disease activity and adverse outcome. PLoS One, 2014, 9(4):e95055.
10. Guzel S, Serin O, Guzel EC, et al. Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction. Korean J Intern Med, 2013, 28(2):165-173.
11. 范天全, 于海奕, 郭艳红, 等. 急性冠状动脉综合征患者血浆白细胞介素33 浓度变化及其与预后的关系. 临床荟萃, 2009, 24(11):924-927.
12. Liu CL, Shen DL, Zhu K, et al. Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease. Coron Artery Dis, 2014, 25(6):498-504.
13. 张祎. 冠心病患者血清IL-33水平的研究. 长沙:中南大学, 2010.
14. 王建华, 肖蕾, 何丽云, 等. 心脑合病危险因素的横断面调查. 中国循证医学杂志, 2014, 14(4):408-413.
15. Golovkin AS, Ponasenko AV, Khutornaya MV, et al. Association of TLR and TREM-1 gene polymorphisms with risk of coronary artery disease in a Russian population. Gene, 2014, 550(1):101-109.
16. Franco A, Touma R, Song Y, et al. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity, 2014, 47(2):95-104.
17. Ismahil MA, Hamid T, Bansal SS, et al. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure:critical importance of the cardiosplenic axis. Circ Res, 2014, 114(2):266-282.
18. Baekkevold ES, Roussigné M, Yamanaka T, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol, 2003, 163(1):69-79.
19. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA, 2008, 105(31):10913-10918.
20. Brunner SM, Schiechl G, Falk W, et al. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int, 2011, 24(10):1027-1039.
21. MartinezFO, Sica A, Mantovani A, et al. Macrophage activation andpolarization. Front Biosci, 2008, 13:453-461.
22. Milovanovic M, Volarevic V, Radosavljevic G, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res, 2012, 52(1-2):89-99.
23. Zhang K, Zhang XC, Mi YH, et al. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin Med J (Engl), 2013, 126(19):3628-3631.

Chinese Journal of Evidence-Based Medicine

Association between Interleukin-33 Expression and Coronary Heart Disease: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content